WallStreetZenWallStreetZen

NASDAQ: CV
Capsovision Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for CV

Based on 1 analyst offering 12 month price targets for Capsovision Inc

Min Forecast
$10.00+62.6%
Avg Forecast
$10.00+62.6%
Max Forecast
$10.00+62.6%

Should I buy or sell CV stock?

Based on 1 analyst offering ratings for Capsovision Inc.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although CV's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates CV as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +5.11% per year. Learn More

Be the first to know when Wall Street analysts revise their CV stock forecasts and price targets.

CV stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-03-27

1 of 1

Forecast return on equity

Is CV forecast to generate an efficient return?

Company
0%
Industry
21.06%
Market
145.3%
CV's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is CV forecast to generate an efficient return on assets?

Company
0%
Industry
11.94%
CV is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

CV earnings per share forecast

What is CV's earnings per share in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
-$0.54
Avg 2 year Forecast
-$0.43
Avg 3 year Forecast
$0.00

CV revenue forecast

What is CV's revenue in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
$16.0M+15.48%
Avg 2 year Forecast
$22.1M+59.23%
Avg 3 year Forecast
$59.3M+327.1%
CV's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

CV revenue growth forecast

How is CV forecast to perform vs Medical Devices companies and vs the US market?

Company
52.95%
Industry
7.63%
Market
15.24%
CV's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
CV's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

CV vs Medical Device Stocks

TickerPricePrice TargetUp/downsideConsensus
CV$6.15$10.00+62.60%Buy
RCEL$9.85$8.25-16.24%Strong Buy
TMCI$4.45$6.00+34.83%Buy
ANIK$21.57$19.00-11.91%Strong Buy
TLSI$5.40$7.50+38.89%Strong Buy
View Top Medical Device Stocks

Capsovision Stock Forecast FAQ

Is Capsovision Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: CV) stock is to Buy CV stock.

Out of 1 analyst, 0 (0%) are recommending CV as a Strong Buy, 1 (100%) are recommending CV as a Buy, 0 (0%) are recommending CV as a Hold, 0 (0%) are recommending CV as a Sell, and 0 (0%) are recommending CV as a Strong Sell.

If you're new to stock investing, here's how to buy Capsovision stock.

What is CV's earnings growth forecast for 2026-2028?

(NASDAQ: CV) Capsovision's forecast annual earnings growth rate of N/A is not forecast to beat the US Medical Devices industry's average forecast earnings growth rate of 29.94%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 61.11%.

Capsovision's earnings in 2026 is -$29,829,000.On average, 4 Wall Street analysts forecast CV's earnings for 2026 to be -$26,805,127, with the lowest CV earnings forecast at -$25,503,907, and the highest CV earnings forecast at -$27,325,614. On average, 4 Wall Street analysts forecast CV's earnings for 2027 to be -$21,650,295, with the lowest CV earnings forecast at -$20,599,309, and the highest CV earnings forecast at -$22,070,689.

In 2028, CV is forecast to generate $0 in earnings, with the lowest earnings forecast at $0 and the highest earnings forecast at $0.

What is CV's revenue growth forecast for 2026-2028?

(NASDAQ: CV) Capsovision's forecast annual revenue growth rate of 52.95% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 7.63%, and it is also forecast to beat the US market's average forecast revenue growth rate of 15.24%.

Capsovision's revenue in 2026 is $13,891,000.On average, 4 Wall Street analysts forecast CV's revenue for 2026 to be $802,852,578, with the lowest CV revenue forecast at $763,916,080, and the highest CV revenue forecast at $818,467,215. On average, 4 Wall Street analysts forecast CV's revenue for 2027 to be $1,106,987,669, with the lowest CV revenue forecast at $1,053,287,331, and the highest CV revenue forecast at $1,128,507,841.

In 2028, CV is forecast to generate $2,969,183,254 in revenue, with the lowest revenue forecast at $2,825,048,145 and the highest revenue forecast at $3,026,837,298.

What is CV's forecast return on assets (ROA) for 2026-2028?

(NASDAQ: CV) forecast ROA is 0%, which is lower than the forecast US Medical Devices industry average of 11.94%.

What is CV's Price Target?

According to 1 Wall Street analyst that have issued a 1 year CV price target, the average CV price target is $10.00, with the highest CV stock price forecast at $10.00 and the lowest CV stock price forecast at $10.00.

The Wall Street analyst predicted that Capsovision's share price could reach $10.00 by Mar 27, 2027. The average Capsovision stock price prediction forecasts a potential upside of 62.6% from the current CV share price of $6.15.

What is CV's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: CV) Capsovision's current Earnings Per Share (EPS) is -$0.45. On average, analysts forecast that CV's EPS will be -$0.54 for 2026, with the lowest EPS forecast at -$0.51, and the highest EPS forecast at -$0.55. On average, analysts forecast that CV's EPS will be -$0.43 for 2027, with the lowest EPS forecast at -$0.41, and the highest EPS forecast at -$0.44. In 2028, CV's EPS is forecast to hit $0.00 (min: $0.00, max: $0.00).

What is CV's forecast return on equity (ROE) for 2026-2028?

(NASDAQ: CV) forecast ROE is 0%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.